The adaptive accelerated biased coin design for phase I clinical trials
Authors:
- 11 May 2011
- journal article
- research article
- Published by Taylor & Francis in Journal of Applied Statistics
- Vol. 38 (12) , 2911-2924
Abstract
Phase I clinical trials are designed to study several doses of the same drug in a small group of patients to determine the maximum tolerated dose (MTD), which is defined as the dose that is associated with dose-limiting toxicity (DLT) in a desired fraction Γ of patients. Durham and Flournoy [ 5 Durham, S. and Flournoy, N. 1995. Up-and-down designs I: Stationary treatment distributions. IMS Lecture Notes – Monogr. Ser., 25: 139–157. [Google Scholar] ] proposed the biased coin design (BCD), which is an up-and-down design that assigns a new patient to a dose depending upon whether or not the current patient experienced a DLT. However, the BCD in its standard form requires the complete follow-up of the current patient before the new patient can be assigned a dose. In situations where patients’ follow-up times are relatively long compared to patient inter-arrival times, the BCD will result in an impractically long trial and cause patients to either have delayed entry into the trial or refusal of entry altogether. We propose an adaptive accelerated BCD (aaBCD) that generalizes the traditional BCD design algorithm by incorporating an adaptive weight function based upon the amount of follow-up of each enrolled patient. By doing so, the dose assignment for each eligible patient can be determined immediately with no delay, leading to a shorter trial overall. We show, via simulation, that the frequency of correctly identifying the MTD at the end of the study with the aaBCD, as well as the number of patients assigned to the MTD, are comparable to that of the traditional BCD design. We also compare the performance of the aaBCD with the accelerated BCD (ABCD) of Stylianou and Follman [ 19 Stylianou, M. and Follmann, D. A. 2004. The accelerated biased coin up-and-down design in phase I trials. J. Biopharmaceutical Statist., 14: 249–260. [Taylor & Francis Online] [Google Scholar] ], as well as the time-to-event continual reassessment method (TITE-CRM) of Cheung and Chappell [ 4 Cheung, Y. K. and Chappell, R. 2000. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics, 56: 1177–1182. [Crossref], [PubMed], [Web of Science ®] [Google Scholar] ].Keywords
This publication has 19 references indexed in Scilit:
- A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trialsContemporary Clinical Trials, 2010
- Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six DesignJournal of Clinical Oncology, 2008
- Monitoring late-onset toxicities in phase I trials using predicted risksBiostatistics, 2007
- Generalizing the TITE‐CRM to adapt for early‐ and late‐onset toxicitiesStatistics in Medicine, 2005
- An evaluation of phase I clinical trial designs in the continuous dose–response settingStatistics in Medicine, 2001
- Properties of frequency distributions induced by general ‘up-and-down’ methods for estimating quantilesJournal of Statistical Planning and Inference, 1998
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- Up-and-down designs. II. Exact treatment moments1995
- Up-and-down designs. I. Stationary treatment distributions1995
- A comparison of two phase I trial designsStatistics in Medicine, 1994